MET and lung carcinoma: We found that clinically significant MET mutations exist in both lung and brain tumor cohorts, with the lung cancer group having a higher overall frequency (p < 0.001), but the frequency of different MET mutation types, mutation characteristics, tumor mutation burden, and co‐mutated genes with high frequency all differ.